Two stocks in Healthcare
Amgen vs Vertex Pharmaceuticals: profit, growth, debt and price compared
Vertex Pharmaceuticals is stronger on 4 of 6 figures: profit margin, sales growth, debt and analysts' view. Amgen is stronger on 2: price for its expected profit and price trend.
Save both stocks to your watchlist and revisit their latest fundamentals.
| AmgenAMGN | Vertex PharmaceuticalsVRTX | |
|---|---|---|
| Net margin | 24.1% | Stronger: 30.7% |
| Revenue growth, past year | +8.45% | Stronger: +11.85% |
| Debt to equity | 376.3% | Stronger: 31.0% |
| Forward P/E | Stronger: 17.7× | 26.9× |
| Dividend yield | 2.27% | — |
| Analysts | Hold · 29 | Stronger: Buy · 28 |
| From its 200-day average | Stronger: +14.8% | +8.8% |
Share price over the past year
- Amgen+29.0%
- Vertex Pharmaceuticals+23.2%
18 Nov 202518 Nov 2026
Amgen or Vertex Pharmaceuticals: which is stronger?
- VRTX
Which is more profitable?
Vertex Pharmaceuticals keeps more of each sale as profit: 30.7% against 24.1%.
- VRTX
Which is growing its sales faster?
Vertex Pharmaceuticals is growing its sales faster: +11.85% over the past year, against +8.45%.
- VRTX
Which has borrowed less?
Vertex Pharmaceuticals has borrowed less: its debt is 31.0% of what its shareholders own, against 376.3% for Amgen.
- AMGN
Which costs less for the profit it is expected to make?
Amgen costs less for the profit it is expected to make: 17.7× its forward earnings, against 26.9×.
Which pays more in dividends?
Amgen pays 2.27% a year in dividends for what a share costs, where Vertex Pharmaceuticals pays none.
- VRTX
Which do analysts rate higher?
Analysts are warmer on Vertex Pharmaceuticals: Buy, against Hold for Amgen.
- AMGN
Which is in the stronger price trend?
Amgen's price is in the stronger trend: 14.8% above its 200-day average, against 8.8% above.
What each company does
AMGNAmgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Reports results on 2 February 2027
VRTXVertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
Reports results on 11 February 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.